Subscribe To

Price Alert Latest News Economic Calendar News

CABA / Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Samik Basu, M.D., Chief Scientific Officer at Cabaletta Bio, will deliver an invited, oral presentation titled “CD 19 CAR T-cells for SLE” as part of the session titled “Immune Effector Cells: 2023 and Beyond!” on Tuesday, May 16, 2023, at 11:05 a.m. PT at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, which is being held at the Los Angeles Convention Center in Los Angeles, CA from May 16-20, 2023. In addition, new preclinical data for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, and updated clinical and translational data from the ongoing DesCAARTes™ trial for DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV) will be presented in poster presentations. Read More

Demo Live Account See Partner Details

Content Topics

Cabaletta

Present

American

Society

Gene

Cell

Therapy

26th

Annual

Meeting

Stock

CABA

Posted: May 2 2023, 16:35

Author Name: GlobeNewsWire

CABA News

By Zacks Investment Research
October 9, 2023

Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?

Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.

By Zacks Investment Research
September 25, 2023

What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'

Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound s

By Seeking Alpha
September 19, 2023

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Cabaletta Bio stock has experienced a significant bull run, rising over 2,100% in the past year. The company's focus on autoimmune conditions with a v

By Zacks Investment Research
September 8, 2023

Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable

Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound s

By InvestorPlace
August 31, 2023

The 7 Most Promising Momentum Stocks to Own Now

Today's volatile market makes momentum investing a compelling strategy for those comfortable with daily turbulence. Unlike value investing, which is r

By GlobeNewsWire
August 30, 2023

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and l

By Zacks Investment Research
August 23, 2023

Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Cabaletta Bio, Inc. (CABA) could be a great choice. It is one

By Zacks Investment Research
August 15, 2023

Does Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in Cabaletta Bio, Inc. (CABA). While the effectiveness

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.